Biolase (BIOL) Misses Q2 EPS by 7c

Biolase (NASDAQ: BIOL) reported Q2 EPS of ($0.10), $0.07 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $13.8 million versus the consensus estimate of $12.9 million.

For earnings history and earnings-related data on Biolase (BIOL) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• Estee Lauder shares jump as fiscal 2027 profit forecast tops estimates
• Analog Devices climbs as fiscal Q3 results, Q4 outlook beat forecasts